About Agilus Diagnostics Limited
Data last updated: 20 December 2025
Agilus Diagnostics Limited is a public limited company based in Mohali, Punjab, India, a subsidiary of Ihh Healthcare Berhad. It specialises in diagnostic centers and pathology labs, a part of the broader healthcare sector. Incorporated on 07 July 1995, the company has been in operation for over 31 years.
Registered with ROC Chandigarh under CIN U74899PB1995PLC045956.
Capital: an authorised share capital of ₹97 Cr and a paid-up capital of ₹78.44 Cr. Formerly known as Specialty Ranbaxy Limited and Srl Ranbaxy Limited. It is led by directors including Anand Kuppuswamy and Ashok Pandit.
Last AGM: 31 July 2025. Financial statements filed for year ended 31 March 2025. Office: Fortis Hospital Sector 62 Phase – Viii, Mohali, Punjab, India – 160062.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,432.43 Cr, a growth of 3% compared to the previous year.
The company has a workforce of approximately 3,385 employees as per the latest available data. It operates as a subsidiary of Ihh Healthcare Berhad. Its group structure includes 3 subsidiaries.
The company is associated with 2 brands - Agilus Diagnostics, Srl Diagnostics. As per MCA filings, the company has open charges of ₹70.18 Cr and satisfied charges of ₹285.83 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website srlworld.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressFortis Hospital Sector 62 Phase – Viii, Mohali, Punjab, India – 160062
-
IndustryHealthcare, Diagnostic Centers & Pathology Labs
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Agilus Diagnostics Limited
Agilus Diagnostics Limited has undergone 4 name changes throughout its history. The current legal name is Agilus Diagnostics Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Agilus Diagnostics Limited | Current |
| Specialty Ranbaxy Limited | Previous |
| Srl Ranbaxy Limited | Previous |
| Super Religare Laboratories Limited | Previous |
| Specialty Ranbaxy Private Limited | Previous |
CIN History of Agilus Diagnostics Limited
Agilus Diagnostics Limited has one previous CIN (Corporate Identification Number): U74899DL1995PLC070603. The current CIN is U74899PB1995PLC045956, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U74899PB1995PLC045956 | Current |
| U74899DL1995PLC070603 | Previous |
Associated Brands with Agilus Diagnostics Limited
Agilus Diagnostics Limited operates two associated brands: Agilus Diagnostics and SRL Diagnostics. These brands represent Agilus Diagnostics Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Leading diagnostic chain providing quality blood test and full body checkup services | agilusdiagnostics.com | |
| Pathology, radiology, wellness and clinical research services | srlworld.com |
Competitors & Alternatives of Agilus Diagnostics Limited
Brands and companies operating in the same space as Agilus Diagnostics Limited include Dr Lal PathLabs, Redcliffe Labs, Metropolis India and 4 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Dr Lal PathLabs
|
Chain of pathology and radiology labs | Gurugram, India, India | 1949 |
Redcliffe Labs
|
Home-based diagnostic tests are booked via an online platform. | Noida, India, India | 2018 |
Metropolis India
|
Diagnostic centers are operated as a nationwide chain. | Mumbai, India, India | 1981 |
Orange health
|
At-home diagnostic tests are booked and collected by phlebotomists. | Bengaluru, India, India | 2020 |
Apollo Diagnostics
|
Provides pathology lab tests, health check packages, and home sample collection. | Hyderabad, India, India | 2015 |
Sterling Accuris Diagnostics
|
Pathology diagnostic services are offered via a chain of labs. | Ahmedabad, India, India | 2015 |
Airmed
|
Provider of a chain of diagnostic labs | Ahmedabad, India, India | 2016 |
Business Activity of Agilus Diagnostics Limited
Agilus Diagnostics Limited is engaged in the principal business activity of hospital and medical care, with detailed activities including other hospital and medical care activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities | ********* |
Auditor Details of Agilus Diagnostics Limited
Agilus Diagnostics Limited is audited by B S R & Co. LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| B S R & Co. LLP | blur-value | blur-value | blur-value |
Board of Directors of Agilus Diagnostics Limited
Agilus Diagnostics Limited is currently managed by 8 directors, with 54 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Financials of Agilus Diagnostics Limited FY 2025 filings available
Agilus Diagnostics Limited reported revenue of ₹1,432.43 Cr (up 3% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Agilus Diagnostics Limited
As of FY 2024, Agilus Diagnostics Limited's shareholding pattern shows 57.68% by promoters, 39.77% by public shareholders, 2.55% by others. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Agilus Diagnostics Limited
Agilus Diagnostics Limited has 3 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Agilus Diagnostics Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Agilus Pathlabs Reach Limited | U85100DL2015PLC279712 |
**.**%
|
| Ddrc Agilus Pathlabs Limited | U85190MH2006PLC161480 |
**.**%
|
| Agilus Pathlabs Private Limited | U85195DL1999PTC217659 |
**.**%
|
Showing major subsidiaries. Total: 3.
Charges & Borrowings of Agilus Diagnostics Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Oct 2025 | Axis Bank Limited | ₹22 Lakh | Open |
| 13 Oct 2025 | Axis Bank Limited | ₹21.36 Lakh | Open |
| 03 Sep 2024 | Others | ₹19.58 Lakh | Open |
| 27 Jul 2023 | Others | ₹41.39 Lakh | Open |
| 31 Mar 2023 | Others | ₹17.81 Lakh | Open |
Total charge records: 59 View all charges
Employees and EPFO Compliance at Agilus Diagnostics Limited
Agilus Diagnostics Limited has a workforce of 3,385 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Agilus Diagnostics Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Agilus Diagnostics Limited
GSTIN & GST Filing Data of Agilus Diagnostics Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Agilus Diagnostics Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Agilus Diagnostics Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Agilus Diagnostics Limited
MSME Payment Delays by Agilus Diagnostics Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Agilus Diagnostics Limited
Subsidiaries & Group Companies of Agilus Diagnostics Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Agilus Diagnostics Limited with ownership details.
MCA Filings & Documents of Agilus Diagnostics Limited
MCA Filings & Documents of Agilus Diagnostics Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Agilus Diagnostics Limited
Recent News on Agilus Diagnostics Limited
Frequently Asked Questions about Agilus Diagnostics Limited
Agilus Diagnostics Limited is an active public limited company in the healthcare sector based in Mohali, Punjab, India. It was incorporated on 07 July 1995 (31+ years old) and is registered under CIN U74899PB1995PLC045956. The company has 3,385 employees.
Agilus Diagnostics Limited reported revenue of ₹1,432.43 Cr for FY 2025 (up 3.00% YoY).
The current directors of Agilus Diagnostics Limited are:
- Anand Kuppuswamy
- Ashok Pandit
- Dilip Kadambi
- Indrajit Banerjee
- Suvalaxmi Chakraborty
- Ashutosh Raghuvanshi
- Akshay Kumar Tiwari
- Satyendra Chauhan
The primary industry of Agilus Diagnostics Limited is healthcare. The company specifically operates in diagnostic centers and pathology labs. The company is currently active in this sector.
Agilus Diagnostics Limited can be reached at the registered office: Fortis Hospital Sector 62 Phase – Viii, Mohali, Punjab, India – 160062, or through the website srlworld.com.
The authorised capital is ₹97 Cr, and the paid-up capital is ₹78.44 Cr.